Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Dec 31;20(1):2410574.
doi: 10.1080/21645515.2024.2410574. Epub 2024 Oct 14.

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity

Ute Klinkardt  1 , Mirjam Schunk  2 , John Ervin  3 , Christoph Schindler  4 , Danny Sugimoto  5 , Bruce Rankin  6 , Ralf Amann  7 , Martina Monti  8 , Anna Kutschenko  4 , Carsten Schumacher  4 , Kristina Huber  2 , Andreas Zeder  2 , Nelli Heikkila  9 , Arnaud M Didierlaurent  9 , Sylvia E Schwarz  1 , Madiha Derouazi  1
Affiliations
Clinical Trial

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity

Ute Klinkardt et al. Hum Vaccin Immunother. .

Abstract

Next-generation COVID-19 vaccines are being developed to expand the breadth of coverage against existing and future variants and to extend the duration of protection. Prime-2-CoV_Beta is an orf virus (ORFV) based multi-antigen COVID-19 vaccine that co-expresses Spike (S) and Nucleocapsid (N) antigens. The safety and immunogenicity of Prime-2-CoV_Beta is investigated in a phase 1 first-in-human (FIH) dose-finding trial (ORFEUS study, ClinicalTrials.gov: NCT05367843). Participants of two age groups (18-55 and 65-85 years) who previously completed at least two doses of mRNA vaccines were enrolled and sequentially assigned to different dose groups to receive one intramuscular dose of 3 × 105, 3 × 106, 1.5 × 107, or 3 × 107 plaque-forming units (PFU) of Prime-2-CoV_Beta on day 1 and a second dose on day 29. Here, we report safety and immunogenicity data collected up to 6 months after the first study vaccination. Prime-2-CoV_Beta is safe and well tolerated and elicits immune responses at higher dose levels in participants aged 18-55. A single dose of 3 × 107 PFU boosted binding and cross-neutralizing antibody responses that are maintained through 6 months after the first booster vaccination. Polyfunctional S-specific CD4+ and CD8+ T cell responses are observed after vaccination. No pre-existing or vaccine-induced neutralizing anti-vector antibodies are detected. Our findings highlight the potential of the ORFV vector as a safe platform for future vaccine design, which provides the ability to deliver multiple antigens and allows for repeat immunization.

Keywords: COVID-19; ORF virus-vector; SARS-CoV-2 variants; booster vaccine; first-in-human trial; immunogenicity; safety.

PubMed Disclaimer

Conflict of interest statement

Rald Amann holds ownership interest in Prime Vector Technologies GmbH, a company involved in the development of ORFV-based vaccines. Additionally, Ralf Amann is an inventor of patents related to ORFV, including a patent application of Prime-2-CoV. Ute Klinkhardt, Sylvia E. Schwarz and Madiha Derouazi were employed by Speransa Therapeutics GmbH. Arnaud M. Didierlaurent declared personal consulting fees for participation to scientific advisory boards for Speransa, Bioaster and Sanofi Pasteur, and participation on a Data Safety Monitoring Board for AMC Biosciences, all unrelated to the present work and is the chairman of the WHO Technical advisory group for Emergency use listing of COVID-19 vaccines..

Figures

Figure 1.
Figure 1.
Participant disposition and analysis sets analyzed.
Figure 2.
Figure 2.
Solicited adverse reactions within 7 days after each study vaccination. (a) The percentages of participants reporting any solicited local AEs of the indicated severity up to 7 days after the first (left) or second (right) vaccination. (b) The percentages of participants reporting any solicited AEs of the indicated severity up to 7 days after the first (left) or second (right) vaccination. The highest severity grade is shown in case there were multiple reports of a given reaction per participant. Number of participants included in the solicited safety population are shown on the right of each diagram.
Figure 2.
Figure 2.
Continued.
Figure 3.
Figure 3.
SARS-CoV-2 neutralizing antibody responses at key time points.
Figure 4.
Figure 4.
SARS-CoV-2 IgG-binding antibody responses at key time points.
Figure 5.
Figure 5.
Fold-increase of neutralizing antibodies in participants with low versus high baseline titers.
Figure 6.
Figure 6.
Change in IgG antibody avidity and neutralizing response in participants with high versus low antibody avidity at baseline.
Figure 7.
Figure 7.
Prime-2-CoV_Beta induced T cell responses to S1/S2 peptide pools.
See this image and copyright information in PMC

References

    1. Krammer F, Ellebedy AH.. Variant-adapted COVID-19 booster vaccines. Science. 2023;382(6667):157–14. doi:10.1126/science.adh2712. - DOI - PubMed
    1. Amann R, Rohde J, Wulle U, Conlee D, Raue R, Martinon O, Rziha H-J.. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein. J Virol. 2013;87(3):1618–1630. doi:10.1128/JVI.02470-12. - DOI - PMC - PubMed
    1. Reguzova A, Ghosh M, Müller M, Rziha HJ, Amann R. Orf virus-based vaccine vector D1701-V induces strong CD8+ T cell response against the transgene but not against ORFV-Derived epitopes. Vaccines (Basel). 2020;8(2):8. doi:10.3390/vaccines8020295. - DOI - PMC - PubMed
    1. Reguzova A, Fischer N, Müller M, Salomon F, Jaenisch T, Amann R. A novel orf virus D1701-VrV-based dengue virus (DENV) vaccine candidate expressing HLA-Specific T cell epitopes: a proof-of-concept study. Biomedicines. 2021;9(12):1862. doi:10.3390/biomedicines9121862. - DOI - PMC - PubMed
    1. Ahn JY, Lee J, Suh YS, Song YG, Choi YJ, Lee KH, Seo SH, Song M, Oh J-W, Kim M, et al. Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. Lancet Microbe. 2022;3(3):173–183. doi:10.1016/S2666-5247(21)00358-X. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data